General Information of Drug (ID: DMWSA0V)

Drug Name
Patisiran Drug Info
Synonyms Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328
Indication
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Approved [1]
Hereditary amyloidosis 5D00.2 Approved [2]
Amyloid cardiomyopathy 5D00.20 Phase 3 [3]
Transthyretin familial amyloid cardiomyopathy 5D00.20 Phase 3 [4]
Cross-matching ID
TTD Drug ID
DMWSA0V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vutrisiran DMM1Z9G Hereditary amyloidosis 5D00.2 Approved [6]
Eplontersen DMON9CY Amyloid polyneuropathy 5D00.20 Approved [7]
Revusiran DM5E73H Amyloidosis 5D00 Phase 3 [5]
ISIS-TTR DM4U5NF Amyloidosis 5D00 Phase 3 [8]
ALN-TTR01 DMCSEUY Amyloidosis 5D00 Phase 1 [9]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transthyretin messenger RNA (TTR mRNA) TTPOYU7 TTHY_HUMAN Not Available [5]

References

1 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 210922.
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT01960348) APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
6 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
7 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217388
8 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
9 Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29.